Emerging therapies for the treatment of patients with advanced neuroendocrine tumors

Bibliography

• KLOPPEL G, PERREN A, HEITZ PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann. NY Acad. Sci. (2004) 1014:13-27.
   PubMed Web of Science ®Google Scholar
• BERGE T, LINELL F: Carcinoid tumours. Frequency in a defined population during a 12-year period.Acta Pathol. Microbiol. Scand. [A] (1976) 84(4):322-330.
   PubMedGoogle Scholar
• MODLIN I, SANDOR A: An analysis of 8305 cases of carcinoid tumors. Cancer (1997) 79:813-829.
   PubMed Web of Science ®Google Scholar
• OBERG K, ERIKSSON B: Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol. (1989) 28:425-431.
   PubMed Web of Science ®Google Scholar
• THORSON A, BIORCK G, BJORKMAN G, WALDENSTROM J: Malignant carcinoid of the small intestine with metastases to the liver, valvular disease on the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis. Am. Heart J. (1954) 47:795-817.
   PubMed Web of Science ®Google Scholar
• KALTSAS G, KORBONITS M, HEINTZ E et al.: Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclites in the diagnosis and localization of advanced neuroendocrine tumors. J. Clin. Endocrinol. Metab. (2001) 86(2):895-902.
   PubMed Web of Science ®Google Scholar
• KVOLS LK, BROWN ML, O'CONNOR MK et al.: Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology (1993) 187(1):129-133.
   PubMed Web of Science ®Google Scholar
• LAMBERTS S, BAKKER WH, REUBI JC, KRENNING EP: Somatostatin receptor imaging in the localization of endocrine tumors. N. Engl. J. Med. (1990) 323:1246-1249.
   PubMed Web of Science ®Google Scholar
• FELDMAN J, O'DIRISIO T: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am. J. Med. (1986) 81 (Suppl. 6B) :41-48.
   PubMed Web of Science ®Google Scholar
• OBERG K, KVOLS L, CAPLIN M et al.: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann. Oncol. (2004) 15(6):966-973.
   PubMed Web of Science ®Google Scholar
• SEREGNI E, FERRARI L, BAJETTA E, MARTINETTI A, BOMBARDIERI E: Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann. Oncol. (2001) 12(Suppl. 2):S69-S72.
   Google Scholar
• STIVANELLO M, BERRUTI A, TORTA M et al.: Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann. Oncol. (2001) 12(Suppl. 2):S73-S77.
   PubMed Web of Science ®Google Scholar
• TOMASSETTI P, MIGLIORI M, SIMONI P et al.: Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur. J. Gastroenterol. Hepatol. (2001) 13(1):55-58.
   PubMed Web of Science ®Google Scholar
• JANSON E, HOLMBERG L, STRIDSBERG M et al.: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol. (1997) 8:685-690.
   PubMed Web of Science ®Google Scholar
• MOERTEL C, LEFKOPOULO M, LIPSITZ S, HAHN RG, KLAASSEN D: Streptozocin-doxorubicin, stretpozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. (1992) 326:519-523.
   PubMed Web of Science ®Google Scholar
• SARMIENTO JM, QUE FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg. Oncol. Clin. N. Am. (2003) 12(1):231-242.
   PubMed Web of Science ®Google Scholar
• KNOX CD, FEURER ID, WISE PE et al.: Survival and functional quality of life after resection for hepatic carcinoid metastasis. J. Gastrointest. Surg. (2004) 8(6):653-659.
   PubMed Web of Science ®Google Scholar
• MUSUNURU S, CHEN H, RAJPAL S et al.: Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch. Surg. (2006) 141(10):1000-1004; discussion 1005.
   PubMed Web of Science ®Google Scholar
• OSBORNE DA, ZERVOS EE, STROSBERG J et al.: Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann. Surg. Oncol. (2006) 13(4):572-581.
   PubMed Web of Science ®Google Scholar
• TOUZIOS JG, KIELY JM, PITT SC et al.: Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann. Surg. (2005) 241(5):776-783; discussion 783-785.
   PubMed Web of Science ®Google Scholar
• GIVI B, POMMIER SJ, THOMPSON AK, DIGGS BS, POMMIER RF: Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery (2006) 140(6):891-897; discussion 897-898.
   PubMed Web of Science ®Google Scholar
• ALSINA AE, BARTUS S, HULL D, ROSSON R, SCHWEIZER RT: Liver transplant for metastatic neuroendocrine tumor. J. Clin. Gastroenterol. (1990) 12(5):533-537.
   PubMed Web of Science ®Google Scholar
• LANG H, OLDHAFER KJ, WEIMANN A et al.: Liver transplantation for metastatic neuroendocrine tumors. Ann. Surg. (1997) 225:347-354.
   PubMed Web of Science ®Google Scholar
• LE TREUT YP, DELPERO JR, DOUSSET B et al.: Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann. Surg. (1997) 225(4):355-364.
   PubMed Web of Science ®Google Scholar
• AJANI JA, CARRASCO CH, CHARNSANGAVEJ C, SAMAAN NA, LEVIN B, WALLACE S: Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann. Intern. Med. (1988) 108(3):340-344.
   PubMed Web of Science ®Google Scholar
• BROWN KT, KOH BY, BRODY LA et al.: Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J. Vasc. Interv. Radiol. (1999) 10(4):397-403.
   PubMed Web of Science ®Google Scholar
• DIAMANDIDOU E, AJANI JA, YANG DJ et al.: Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am. J. Roentgenol. (1998) 170(2):339-344.
   PubMed Web of Science ®Google Scholar
• DOMINGUEZ S, DENYS A, MADEIRA I et al.: Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur. J. Gastroenterol. Hepatol. (2000) 12(2):151-157.
   PubMed Web of Science ®Google Scholar
• DROUGAS JG, ANTHONY LB, BLAIR TK et al.: Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am. J. Surg. (1998) 175(5):408-412.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BK, LARSSON EG, SKOGSEID BM, LOFBERG AM, LORELIUS LE, OBERG KE: Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer (1998) 83(11):2293-2301.
   PubMed Web of Science ®Google Scholar
• GUPTA S, YAO JC, AHRAR K et al.: Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience. Cancer J. (2003) 9:261-267.
   PubMed Web of Science ®Google Scholar
• LOEWE C, SCHINDL M, CEJNA M, NIEDERLE B, LAMMER J, THURNHER S: Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am. J. Roentgenol. (2003) 180(5):1379-1384.
   PubMed Web of Science ®Google Scholar
• MOERTEL C, JOHNSON CM, McKusick MA et al.: The management of patients with advanced carcinoid tumors and islet cell carcinoma. Ann. Int. Med. (1994) 120:302-309.
   PubMed Web of Science ®Google Scholar
• RUSZNIEWSKI P, ROUGIER P, ROCHE A et al.: Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. Cancer (1993) 71:2624-2630.
   PubMed Web of Science ®Google Scholar
• REUBI J, KVOLS LK, WASER B et al.: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. (1990) 50:5969-5977.
   PubMed Web of Science ®Google Scholar
• KVOLS L, MOERTEL CG, O'CONNELL MJ, SCHUTT AJ, RUBIN J, HAHN RG: Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analog. N. Engl. J. Med. (1986) 315:663-666.
   PubMed Web of Science ®Google Scholar
• RUBIN J, AJANI J, SCHIRMER W et al.: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J. Clin. Oncol. (1999) 17:600-606.
   PubMed Web of Science ®Google Scholar
• DUCREUX M, RUSZNIEWSKI P, CHAYVIALLE JA et al.: The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am. J. Gastroenterol. (2000) 95:3276-3281.
   PubMed Web of Science ®Google Scholar
• FAISS S, PAPE UF, BOHMIG M et al.: Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon alpha, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors — the International Lanreotide and Interferon Alpha Study Group. J. Clin. Oncol. (2003) 21:2689-2696.
   PubMed Web of Science ®Google Scholar
• FAISS S, RATH U, MANSMANN U et al.: Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocribe gastroenteropancreatic tumors. Digestion (1999) 60:469-476.
   PubMed Web of Science ®Google Scholar
• O'TOOLE D, DUCREUX M, BOMMELAER G et al.: Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer (2000) 88:770-776.
   PubMed Web of Science ®Google Scholar
• WYMENGA A, ERIKSSON B, SALMELA PI et al.: Efficacy and saftey of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J. Clin. Oncol. (1999) 17:1111.
   PubMed Web of Science ®Google Scholar
• OBERG K, FUNA K, ALM G: Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N. Engl. J. Med. (1983) 309:129-133.
   PubMed Web of Science ®Google Scholar
• FRANK M, KLOSE KJ, WIED M, ISHAQUE N, SCHADE-BRITTINGER C, ARNOLD R: Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am. J. Gastroenterol. (1999) 94:1381-1387.
   PubMed Web of Science ®Google Scholar
• JANSON E, OBERG K: Long term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. (1993) 32:225-229.
   PubMed Web of Science ®Google Scholar
• OBERG K, ERIKSSON B: The role of interferons in the management of carcinoid tumors. Acta Oncol. (1991) 30:519-522.
   PubMed Web of Science ®Google Scholar
• VALIMAKI M, JARVINEN H, SALMELA P, SANE T, SJOBLOM SM, PELKONEN R: Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer (1991) 67:547-549.
   PubMed Web of Science ®Google Scholar
• Saltz L, TROCHANOWSKI B, BUCKLEY M et al.: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer (1993) 72:244-248.
   PubMed Web of Science ®Google Scholar
• KOLBY L, PERSSON G, FRANZEN S, AHREN B: Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br. J. Surg. (2003) 90:687-693.
   PubMed Web of Science ®Google Scholar
• CHENG P, SALTZ L: Failure to confirm major objective antitumor activity of streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer (1999) 86:944-948.
   PubMed Web of Science ®Google Scholar
• MCCOLLUM AD, KULKE MH, RYAN DP et al.: Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am. J. Clin. Oncol. (2004) 27(5):485-488.
   PubMed Web of Science ®Google Scholar
• KOUVARAKI M, AJANI JA, HOFF P et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. (2004) 22:4762-4771.
   PubMed Web of Science ®Google Scholar
• SUN W, LIPSITZ S, CATALANO P, MAILLIARD JA, HALLER DG: Eastern Cooperative Oncology Group, Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J. Clin. Oncol. (2005) 23:4897-4904.
   PubMed Web of Science ®Google Scholar
• RAMANATHAN RK, CNAAN A, HAHN RG, CARBONE PP, HALLER DG: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Studyof the Eastern Cooperative Oncology Group-E6282. Ann. Oncol. (2001) 12(8):1139-1143.
   PubMed Web of Science ®Google Scholar
• BUKOWSKI RM, TANGEN CM, PETERSON RF et al.: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer (1994) 73:1505-1508.
   PubMed Web of Science ®Google Scholar
• STEVENS MF, HICKMAN JA, LANGDON SP et al.: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-D]-1,2,3,5-tetrazin-4(3H)-one(CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. (1987) 47(22):5846-5852.
   PubMed Web of Science ®Google Scholar
• KULKE MH, STUART K, ENZINGER PC et al.: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. (2006) 24(3):401-406.
   PubMed Web of Science ®Google Scholar
• KULKE M, STUART K, EARLE CC et al.: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2006) 24(18S):A4044.
   Google Scholar
• ERIKSSON B, OBERG K: Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann. Oncol. (1999) 10(Suppl. 2):S31-S38.
   Google Scholar
• LI M, LI W, KIM HJ, YAO Q, CHEN C, FISHER WE: Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. J. Surg. Res. (2004) 119(2):130-137.
   PubMed Web of Science ®Google Scholar
• RONGA G, SALERNO G, PROCACCINI E et al.: 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors. Q. J. Nucl. Med. (1995) 39 (4 Suppl. 1) :134-136.
   PubMedGoogle Scholar
• SCHMID HA, SCHOEFFTER P: Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology (2004) 80(Suppl. 1):47-50.
   PubMedGoogle Scholar
• KVOLS L, WIEDENMANN B, OBERG K et al.: Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a Phase II study. 2006 ASCO Annual Meeting. J. Clin. Oncol. (2006) 24:A4082.
   Google Scholar
• TEUNISSEN JJ, KWEKKEBOOM DJ, DE JONG M et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract. Res. Clin. Gastroenterol. (2005) 19(4):595-616.
   PubMed Web of Science ®Google Scholar
• KRENNING EP, KWEKKEBOOM DJ, VALKEMA R, PAUWELS S, KVOLS LK, DE JONG M: Peptide receptor radionuclide therapy. Ann. NY Acad. Sci. (2004) 1014:234-245.
   PubMed Web of Science ®Google Scholar
• BREEMAN WA, DE JONG M, KWEKKEBOOM DJ et al.: Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. J. Nucl. Med. (2001) 28(9):1421-1429.
   PubMedGoogle Scholar
• DEJONG M: Somatostatin-receptor targeted radionucleotide therapy of tumors: preclinical and clinical findings. Semin. Nucl. Med. (2002) 32:133-140.
   PubMed Web of Science ®Google Scholar
• VALKEMA R, DE JONG M, BAKKER WH et al.: Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin. Nucl. Med. (2002) 32(2):110-122.
   PubMed Web of Science ®Google Scholar
• ANTHONY LB, WOLTERING EA, ESPENAN GD, CRONIN MD, MALONEY TJ, MCCARTHY KE: Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin. Nucl. Med. (2002) 32(2):123-132.
   PubMed Web of Science ®Google Scholar
• OTTE A, HERRMANN R, HEPPELER A et al.: Yttrium-90 DOTATOC: first clinical results. Eur. J. Nucl. Med. (1999) 26(11):1439-1447.
   PubMedGoogle Scholar
• PAGANELLI G, ZOBOLI S, CREMONESI M et al.: Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur. J. Nucl. Med. (2001) 28(4):426-434.
   PubMedGoogle Scholar
• WALDHERR C, PLESS M, MAECKE HR, HALDEMANN A, Mueller-Brand J: The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical Phase II study. Ann. Oncol. (2001) 12(7):941-945.
   PubMed Web of Science ®Google Scholar
• WALDHERR C, PLESS M, MAECKE HR et al.: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J. Nucl. Med. (2002) 43(5):610-666.
   PubMed Web of Science ®Google Scholar
• VIRGOLINI I, BRITTON K, BUSCOMBE J, MONCAYO R, PAGANELLI G, RIVA P: In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin. Nucl. Med. (2002) 32(2):148-155.
   PubMed Web of Science ®Google Scholar
• KWEKKEBOOM DJ, TEUNISSEN JJ, BAKKER WH et al.: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. (2005) 23(12):2754-2762.
   PubMed Web of Science ®Google Scholar
• TERRIS B, SCOAZEC J, RUBBIA L: Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology (1998) 32:133-138.
   PubMed Web of Science ®Google Scholar
• CHRISTOFORI G, NAIK P, HANAHAN D: Vascular endothelial growth factor and its receptors,flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol. Endocrinol. (1995) 9(12):1760-1770.
   PubMed Web of Science ®Google Scholar
• LA ROSA S, UCCELLA S, FINZI G, ALBARELLO L, SESSA F, CAPELLA C: Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum. Pathol. (2003) 34(1):18-27.
   PubMed Web of Science ®Google Scholar
• AMBS S, BENNETT WP, MERRIAM WG et al.: Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br. J. Cancer (1998) 78(2):233-239.
   PubMed Web of Science ®Google Scholar
• CHAUDHRY A, FUNA K, OBERG K: Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. (1993) 32(2):107-114.
   PubMed Web of Science ®Google Scholar
• CHAUDHRY A, OBERG K, GOBL A, HELDIN CH, FUNA K: Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res. (1994) 14 (5B) :2085-2091.
   PubMed Web of Science ®Google Scholar
• CHAUDHRY A, PAPANICOLAOU V, OBERG K, HELDIN CH, FUNA K: Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res. (1992) 52(4):1006-1012.
   PubMed Web of Science ®Google Scholar
• HOPFNER M, BARADARI V, HUETHER A, SCHOFL C, SCHERUBL H: The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr. Relat. Cancer (2006) 13:135-149.
   PubMed Web of Science ®Google Scholar
• KRISHNAMURTHY S, DAYAL Y: Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids. Am. J. Surg. Pathol. (1997) 21(3):327-333.
   PubMed Web of Science ®Google Scholar
• LANKAT-BUTTGEREIT B, HORSCH D, BARTH P, ARNOLD R, BLOCKER S, GOKE R: Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion (2005) 71(3):131-140.
   PubMed Web of Science ®Google Scholar
• NILSSON O, WANGBERG B, KOLBY L, SCHULTZ GS, AHLMAN H: Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int. J. Cancer (1995) 60(5):645-651.
   PubMed Web of Science ®Google Scholar
• YAO JC, ZHANG JX, RASHID A et al.: Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin. Cancer Res. (2007) 13(1):234-240.
   PubMed Web of Science ®Google Scholar
• HOBDAY T, HOLEN K, DONEHOWER R et al.: A Phase II trial of gefitinib in patients with progressive metastatic neuroendocrine tumors: a Phase II consortium study. 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2006) 24(18S):A4043.
   Web of Science ®Google Scholar
• HOPFNER M, SUTTER AP, GERST B, ZEITZ M, SCHERUBL H: A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD-1839). Br. J. Cancer (2003) 89(9):1766-1775.
   PubMed Web of Science ®Google Scholar
• CASANOVAS O, HICKLIN DJ, BERGERS G, HANAHAN D:Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 8(4):299-309.
   PubMed Web of Science ®Google Scholar
• YAO JC, NG C, HOFF PM et al.: Improved progression-free survival and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2005) 23:A4007.
   Google Scholar
• KULKE M, LENZ H, MEROPOL N et al.: Results of a phase II study with sunitinib malate (SU-11248) in patients with advanced neuroendocrine tumours in ECCO. Eur. J. Cancer Suppl. (2005) 3(2):204 (A718).
   Google Scholar
• VIGNOT S, FAIVRE S, AGUIRRE D, RAYMOND E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. (2005) 16(4):525-537.
   PubMed Web of Science ®Google Scholar
• PODSYPANINA K, LEE RT, POLITIS C et al.: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA (2001) 98(18):10320-10325.
   PubMed Web of Science ®Google Scholar
• WANG L, IGNAT A, AXIOTIS CA: Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl. Immunohistochem. Mol. Morphol. (2002) 10(2):139-146.
   PubMedGoogle Scholar
• SMOLEWSKI P: Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs (2006) 17:487-494.
   PubMed Web of Science ®Google Scholar
• DURAN I, KORTMANSKY J, SINGH D et al.: A Phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer (2006) 95(9):1148-1154.
   PubMed Web of Science ®Google Scholar
• YAO JC, PHAN AT, CHANG DZ et al.: Phase II study of RAD-001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma. 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2006) 24:A4042.
   PubMed Web of Science ®Google Scholar
• MOERTEL CG, HANLEY JA: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin. Trials (1979) 2(4):327-334.
   PubMedGoogle Scholar
• ENGSTROM P, LAVIN PT, MOERTEL CG, FOLSCH E, DOUGLASS HO Jr: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J. Clin. Oncol. (1984) 2:1255-1259.
   PubMed Web of Science ®Google Scholar